Volume 21, Number 6—June 2015
Research
Risk Factors for Acquisition of Drug Resistance during Multidrug-Resistant Tuberculosis Treatment, Arkhangelsk Oblast, Russia, 2005–2010
Table 3
Variable† | Total | Acquired ofloxacin resistance, no. (%) |
p value‡ | |
---|---|---|---|---|
Yes | No | |||
Enrollment cohort | ||||
2005–2006 | 64 | 0 (0) | 64 (100) | 0.08 |
2007–2008 | 97 | 6 (6.2) | 91 (93.8) | |
Body mass index <18.5 at MDR TB diagnosis | ||||
Yes | 35 | 4 (11.4) | 31 (88.6) | 0.02 |
No | 126 | 2 (1.6) | 124 (98.4) | |
Hospitalized at time of enrollment | ||||
Yes | 159 | 5 (3.1) | 154 (96.9) | 0.07 |
No | 2 | 1 (50) | 1 (50) | |
Ever received MOX during current episode | ||||
Yes | 26 | 4 (15.4) | 22 (84.6) | 0.007 |
No | 135 | 2 (1.5) | 133 (98.5) | |
Changed FQ during current episode | ||||
Yes | 10 | 2 (20) | 8 (80) | 0.05 |
No | 151 | 4 (2.6) | 147 (97.4) | |
Ever received a third-line drug during episode | ||||
Yes | 79 | 6 (7.6) | 73 (92.4) | 0.01 |
No | 82 | 0 (0) | 82 (100) |
*FQ, fluoroquinolone; OFX, ofloxacin; MDR TB, multidrug-resistant tuberculosis; MOX, moxifloxicin.
†Certain variables were tested for association but omitted from table because results were not statistically significant at α = 0.1.
‡Fisher exact test.
Page created: May 15, 2015
Page updated: May 15, 2015
Page reviewed: May 15, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.